Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Tesamorelin vs Hexarelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin has stronger documented evidence (FDA-Approved) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tesamorelin

FDA-Approved

Hexarelin

Phase 2 (not approved)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Tesamorelin Hexarelin
Class GHRH analog (FDA-approved) GHRP; potent ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion GHS-R1a agonist; more potent GH release than other GHRPs
Route SC injection SC / Intranasal
Half-life ~26 min ~1 hr
Dosage (research) 2 mg SC daily (FDA label) 100-200 mcg SC 1-2x daily (short cycles)
Evidence tier FDA-Approved Phase 2 (not approved)
Research depth 127 indexed (PubMed 84 · CT 23 · EPMC 20) 158 indexed (PubMed 141 · CT 0 · EPMC 17)
Availability Prescription Research Chemical
Reported risks Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 Cortisol/prolactin elevation; pituitary desensitization

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tesamorelin or Hexarelin?

Tesamorelin has stronger documented evidence (FDA-Approved) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Tesamorelin and Hexarelin?

Tesamorelin is classed as GHRH analog (FDA-approved); Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: Tesamorelin, ~26 min; Hexarelin, ~1 hr. Routes in published studies: Tesamorelin, SC injection; Hexarelin, SC / Intranasal.

Which has stronger evidence, Tesamorelin or Hexarelin?

Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.

Which is more accessible, Tesamorelin or Hexarelin?

Tesamorelin is FDA-approved and Hexarelin is not. Catalog status: Tesamorelin, Prescription; Hexarelin, Research Chemical.

Are Tesamorelin and Hexarelin ever combined?

Tesamorelin and Hexarelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…